Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GALR2 | O43603 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153199 | 0.84 | RAB9A (0.51) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL25352613 | 0.84 | VCAM1 (0.44) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL3145085 | 0.82 | RAB9A (0.39) | VCAM1RAB9ATDP1MAPK1MAPT | |
| SCHEMBL4710342 | 0.81 | RAB9A (0.45) | VCAM1RAB9ATDP1TSHRMAPT | |
| SCHEMBL3149287 | 0.81 | VCAM1 (0.40) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL8313813 | 0.80 | VCAM1 (0.56) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL8390568 | 0.79 | VCAM1 (0.51) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL3149349 | 0.79 | RAB9A (0.74) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL894816 | 0.78 | TDP1 (0.60) | VCAM1RAB9ATDP1MERTKTSHR | |
| SCHEMBL272708 | 0.78 | TDP1 (0.60) | VCAM1RAB9ATDP1MERTKTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-8067395-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7687638-B2 | Dipeptidyl peptidase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | PHARMACYCLICS, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7625880-B2 | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| CN-101421269-A | Inhibitors of tyrosine kinases and uses thereof | PHARMACYCLICS INC (US) | 2009-04-29 | — | — | CN | disclosed |
| EP-1981888-A2 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | Pharmacyclics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1311300-B1 | RADIOLIGAND AND BINDING ASSAY | MERCK & CO INC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-09-04 | — | — | US | disclosed |
| EP-1309596-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-6506769-B2 | Pyridine -imidazole, -thiazole or -oxazole derivatives; treating autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6489328-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | disclosed |
| EP-1222187-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020034730-A1 | Radioligand and binding assay | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002014319-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108547-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | VCAM1 1105/4885RAB9A 1593/4885TDP1 557/4885 |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, JAK1, LCK | VCAM1 139/4885RAB9A 2312/4885TDP1 1671/4885 |
| US-20100035841-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | VCAM1 1105/4885RAB9A 1593/4885TDP1 557/4885 |
| US-20120083470-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | VCAM1 1105/4885RAB9A 1593/4885TDP1 557/4885 |
| US-20020016460-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | VCAM1 356/4885RAB9A 2309/4885TDP1 1816/4885 |
| US-20020034730-A1 | Radioligand and binding assay | KCNH2, KCNH3, KCNJ2 | VCAM1 1938/4885RAB9A 2084/4885TDP1 3774/4885 |
| US-20030166929-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | LTK, FRK, JAK1 | VCAM1 356/4885RAB9A 2309/4885TDP1 1816/4885 |
| US-20120101065-A1 | INHIBITORS OF TYROSINE KINASES AND USES THEREOF | LCK, ABL1, SRC | VCAM1 1105/4885RAB9A 1593/4885TDP1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.